Comparison Between Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients With Acute Coronary Syndrome

Rawalpindi Medical University

Status and phase: Completed; Phase 4

Conditions: Mi Q Wave

Treatments: Drug: rosuvastatin 20 mg,; Device: Turbox CRP kit; Drug: atorvastatin 40 mg

Study type: Interventional

Funder types: Other

Identifiers

NCT06053983

46 /IREFIRMU 2021

Details and patient eligibility

About

This study will help us to compare atorvastatin and rosuvastatin in terms of their ability to reduce biomarkers of inflammation in patients of acute coronary syndrome

Enrollment: 126 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with age 18 years and above, of both genders, diagnosed with acute coronary syndrome (as per operational definition) who were not taking statins previously.
2. Patients who sign written informed consent to participate in the study.

Exclusion criteria

• 1.Patients who are taking either statins and/or any other drug which lower serum lipid levels, patients with a history of statin hypersensitivity, patients in whom statins are contraindicated.

  2.Patients who will be surgically managed will be also excluded. 3.if coronary revascularization will be planned or anticipated at the time of screening.

  4.Pregnant or lactating women. 5.Patients having concomitant infections which cause the rise of inflammatory markers.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

126 participants in 2 patient groups

rosuvastatin 20 mg

Experimental group

Treatment:

Device: Turbox CRP kit

Drug: rosuvastatin 20 mg,

atorvastatin 40 mg

Experimental group

Treatment:

Drug: atorvastatin 40 mg

Device: Turbox CRP kit